A Phase Ib, Multi-center, Open Label, Dose Escalation Study of Oral LDE225 in Combination With BKM 120 in Patients With Advanced Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 29 Jun 2015
At a glance
- Drugs Buparlisib (Primary) ; Sonidegib (Primary)
- Indications Advanced breast cancer; Colorectal cancer; Glioblastoma; Pancreatic cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Novartis
- 29 Jun 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
- 27 Apr 2015 Planned End Date changed from 1 Apr 2015 to 1 May 2015 as reported by ClinicalTrials.gov record.
- 27 Apr 2015 Planned primary completion date changed from 1 Apr 2015 to 1 May 2015 as reported by ClinicalTrials.gov record.